BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21272775)

  • 1. The post-BART anti-fibrinolytic dilemma?
    Beattie WS; Karkouti K
    J Cardiothorac Vasc Anesth; 2011 Feb; 25(1):3-5. PubMed ID: 21272775
    [No Abstract]   [Full Text] [Related]  

  • 2. ε-Aminocaproic acid and clinical value in cardiac anesthesia.
    Raghunathan K; Connelly NR; Kanter GJ
    J Cardiothorac Vasc Anesth; 2011 Feb; 25(1):16-9. PubMed ID: 20870423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifibrinolytics.
    Schmarts
    Acta Anaesthesiol Belg; 2003; 54(4):319-22. PubMed ID: 14719353
    [No Abstract]   [Full Text] [Related]  

  • 4. Antifibrinolytics in liver transplantation.
    Groenland TH; Porte RJ
    Int Anesthesiol Clin; 2006; 44(3):83-97. PubMed ID: 16832208
    [No Abstract]   [Full Text] [Related]  

  • 5. eComment: A comparison of the safety of aprotinin and tranexamic acid in cardiac surgery.
    Koniari I; Apostolakis E; Mandellou M
    Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):101. PubMed ID: 19546299
    [No Abstract]   [Full Text] [Related]  

  • 6. Current status of non-transfusional haemostatic agents.
    Cattaneo M; Mannucci PM
    Haematologica; 1999 Jun; 84 Suppl EHA-4():120-3. PubMed ID: 10907488
    [No Abstract]   [Full Text] [Related]  

  • 7. Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials.
    Takagi H; Manabe H; Kawai N; Goto SN; Umemoto T
    Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):98-101. PubMed ID: 19380335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era.
    Koster A; Schirmer U
    Curr Opin Anaesthesiol; 2011 Feb; 24(1):92-7. PubMed ID: 20881484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemostatic drugs.
    Mannucci PM
    N Engl J Med; 1998 Jul; 339(4):245-53. PubMed ID: 9673304
    [No Abstract]   [Full Text] [Related]  

  • 10. Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid.
    Martin K; Knorr J; Breuer T; Gertler R; Macguill M; Lange R; Tassani P; Wiesner G
    J Cardiothorac Vasc Anesth; 2011 Feb; 25(1):20-5. PubMed ID: 21272777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery.
    Body SC; Mazer CD
    Anesth Analg; 2006 Dec; 103(6):1354-9. PubMed ID: 17122202
    [No Abstract]   [Full Text] [Related]  

  • 12. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
    Karkouti K; Wijeysundera DN; Yau TM; McCluskey SA; Tait G; Beattie WS
    Anesth Analg; 2010 Jan; 110(1):21-9. PubMed ID: 19910626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk associated with aprotinin in cardiac surgery.
    Mangano DT; Tudor IC; Dietzel C; ;
    N Engl J Med; 2006 Jan; 354(4):353-65. PubMed ID: 16436767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
    Fergusson DA; Hébert PC; Mazer CD; Fremes S; MacAdams C; Murkin JM; Teoh K; Duke PC; Arellano R; Blajchman MA; Bussières JS; Côté D; Karski J; Martineau R; Robblee JA; Rodger M; Wells G; Clinch J; Pretorius R;
    N Engl J Med; 2008 May; 358(22):2319-31. PubMed ID: 18480196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
    Levi M; Cromheecke ME; de Jonge E; Prins MH; de Mol BJ; Briët E; Büller HR
    Lancet; 1999 Dec; 354(9194):1940-7. PubMed ID: 10622296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.
    Later AF; Maas JJ; Engbers FH; Versteegh MI; Bruggemans EF; Dion RA; Klautz RJ
    Eur J Cardiothorac Surg; 2009 Aug; 36(2):322-9. PubMed ID: 19250838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons learned in antifibrinolytic therapy: The BART trial.
    Murkin JM
    Semin Cardiothorac Vasc Anesth; 2009 Jun; 13(2):127-31. PubMed ID: 19622534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery.
    Brown JR; Birkmeyer NJ; O'Connor GT
    Circulation; 2007 Jun; 115(22):2801-13. PubMed ID: 17533182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials.
    Carless PA; Moxey AJ; Stokes BJ; Henry DA
    BMC Cardiovasc Disord; 2005 Jul; 5():19. PubMed ID: 15992412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-aminocaproic acid.
    Royston D
    Int Anesthesiol Clin; 1995; 33(1):155-79. PubMed ID: 7543455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.